INTRODUCTION
============

Human papillomavirus (HPV) is known to be a major risk factor in the development of cervical cancer \[[@R1]\]. However, the role of HPV for the clinical outcome of cervical carcinomas is debatable. Previous studies have reported various results on whether the presence of HPV, and also whether the presence of a specific type over another, may have prognostic value for the clinical outcome of women with cervical cancer. Some studies have reported that patients with HPV negative cervical tumours have a worse prognosis than those with HPV positive tumours \[[@R2]-[@R6]\]; other studies have found the presence of HPV to be unrelated to clinical outcome \[[@R7]-[@R10]\]. In most of these studies, HPV DNA was detected by PCR \[[@R2], [@R4], [@R5], [@R9]-[@R16]\] or *in situ* hybridization (ISH) \[[@R3], [@R6], [@R7]\]. When it comes to different HPV genotypes, we do know that different types have different oncogenic potential in causing cervical cancer. The question is however whether these also may exert different pressure in terms of the clinical outcome of women with cervical cancer. In previous studies, a reduced survival has in particular been correlated with HPV 18 positive tumours \[[@R11]-[@R15]\]. Reduced survival has also been demonstrated for women with multiple HPV types \[[@R16]\]. Nevertheless, no definite conclusions regarding a different impact of different types on clinical outcome have been disclosed.

The presence of HPV E6/E7 oncoproteins is crucial for the development and maintenance of a malignant phenotype \[[@R17]-[@R19]\]. Moreover, it is known that the E6 and E7 proteins of different HPV types have different oncogenic potential. Concerning HPV mRNA, one study performing HPV 16, 18, 31, and 33 mRNA detection using ISH and ^125^I-labelled riboprobes, reports an increased age at diagnosis and an increased mortality associated with cervical carcinomas negative for HPV mRNA \[[@R3], [@R6], [@R7]\].

In addition to the presence of HPV oncoproteins, integration of HPV DNA into the host genome is associated with the development of cervical cancer. As a result of HPV integration, expression of the HPV E6/E7 oncoproteins increases, abrogating cell cycle control and apoptosis mechanisms \[[@R20]\]. Alternatively to the integrated form, HPV can be found as episomes alone or in a mixed form containing both episomal and integrated virus. According to Cooper *et al.* \[[@R21]\] and Kristiansen *et al.* \[[@R22]\], the physical state of HPV DNA can be determined by the pattern of the ISH signals. These authors observed that ISH signals may be spread over the entire nucleus (diffuse), indicating the episomal form, concentrated in small spots (punctuate), indicating the integrated form, or in a mixture of the two, indicating both episomal and integrated forms. Previously, it has been suggested that the viral integration status may be important as a prognostic marker in cervical carcinomas, reported by two studies comparing the physical state of HPV by ISH and clinical outcome \[[@R23], [@R24]\]. However, in these studies, only 47 and 50 women with cervical carcinoma were included \[[@R23], [@R24]\] and thus, additional studies should be performed in order to reveal whether integration, as detected by ISH, can be used as a prognostic marker for the clinical outcome of carcinomas.

In a previous study, we have investigated the prevalence of HPV DNA and E6/E7 mRNA in a series of cervical squamous cell carcinomas (SCCs) using different PCR techniques, ISH, nucleic acid sequence based amplification (NASBA), and the NASBA based PreTect HPV-Proofer assay \[[@R25]\]. The aim of the present study was to assess whether the presence of HPV DNA and/or HPV E6/E7 mRNA, the presence of certain HPV genotypes or the physical state of HPV DNA, might have prognostic significance. To our knowledge, the present study is the first to report the association between HPV E6/E7 mRNA, detected by NASBA, and clinical outcome of women treated for SCCs.

MATERIALS AND METHODOLOGY
=========================

Tumour material.
----------------

From the original 204 cervical SCCs, FIGO stage Ia-IVb, included in our previous study \[[@R25]\], 202 were included in the present analysis; for two women, clinical information was not available. Staging was done according to the FIGO guidelines \[[@R26]\]. All patients were treated at the Department of Gynaecologic Oncology, The Norwegian Radium Hospital, during the period 1995-1998. The median age was 54.1 years, ranging from 26 to 92 years. Patient information is listed in Table **[1](#T1){ref-type="table"}**. Out of 58 patients with FIGO stage I, 13 were treated with radiation and 45 were treated by radical hysterectomy and pelvic lymphadenectomy. Postoperative adjuvant treatment was given to 17 of these patients. Of the patients with FIGO stage II-IV, 121 were treated with radiation, two with chemotheraphy and radiation, 14 with palliative radiotherapy, two with radical hysterectomy and pelvic lymphadenectomy and five had palliative treatment. After treatment, patients were followed up at The Norwegian Radium Hospital or at local hospitals. One patient was lost to follow-up after 3 months; all the others were followed until death or until August 2006. A total of 79 (39.1%) patients suffered a relapse and 75 (37.1%) died of cervical cancer. For patients still alive, median follow-up was 117 months (range from 92 to 139 months). Median follow-up for patients without relapse was 115 months (range from 76 to 138 months).

Fresh frozen tissue, taken from the primary tumour at the time of diagnosis and stored at -70^o^C, was used for PCR and NASBA analyses. For ISH, formalin-fixed, paraffin-embedded tissue from the same tumours was used.

The study has been approved by The Regional Committee for Medical Research Ethics South of Norway (S-06381a), The Social- and Health Directorate (06/4509 and 06/4417), and The Data Inspectorate (06/01467-3).

HPV DNA analysis by PCR.
------------------------

Type-specific PCR, identifying HPV 16, 18, 31, 33, 35, 45, 52 and 58 DNA, was performed as described previously \[[@R25]\]. HPV DNA detection was also performed by consensus Gp5+/6+ PCR as described previously \[[@R25]\]. Samples negative by type-specific PCR were tested by the Gp5+/6+ enzyme immunoassay (EIA) and reverse line blot (RLB) assay \[[@R27]\].

HPV DNA analysis by ISH.
------------------------

ISH was carried out with biotinylated probes against HPV 16 and 18 (gifts from profs. Harald zur Hausen and Ethel-Michele de Villiers, Germany) \[[@R28], [@R29]\] and HPV 31 and 33 (Eurodiagnostics BV) and an alkaline phosphatase anti-alkaline phosphatase detection system, as described previously \[[@R25]\]. The physical state of HPV DNA was determined by the pattern of the ISH signal as described in Cooper *et al.* \[[@R21]\] and Kristiansen *et al.* \[[@R22]\]: A diffuse signal indicates episomal DNA, a punctuate signal indicates integrated DNA and a mixture of these two patterns indicates the presence of both episomal and integrated DNA.

HPV E6/E7 mRNA analysis by NASBA.
---------------------------------

The real-time multiplex NASBA assay, including PreTect^TM^ HPV-Proofer, identifying HPV 16, 18, 31, 33, 35, 45, 52 and 58 E6/E7 mRNA, was performed as suggested by the manufacturer (NorChip AS, Klokkarstua, Norway) and as published previously \[[@R25], [@R30]\].

*TP53* mutation analysis.
-------------------------

*TP53* mutation analysis was performed in tumour DNA by resequencing exon 2-11 using the 3730 DNA Analyzer (Applied Biosystems, Applied Biosystems, Foster City, California, USA). All fragments were sequenced in both directions and the primers used were linked to universal M13 sequences in the 5' position to simplify the sequencing reaction (Table **[2](#T2){ref-type="table"}**). 25 ng DNA was amplified in a 10 μl PCR reaction using HotStarTaq DNA Polymerase (Qiagen) and touchdown PCR with annealing temperatures moving from 68°C to 56°C. SeqScape^®^ Software v2.5 (Applied Biosystems) was used for alignment to reference sequence and the scoring were carried out by two experienced operators independently. GeneBank accession number NM_000546 was used as reference sequence.

Statistical analysis.
---------------------

For statistical evaluation and based on previous studies \[[@R2], [@R7], [@R9], [@R13], [@R15], [@R23]\], the cases were divided into different groups. Furthermore, the different HPV detection methods were evaluated either individually and/or collectively (Table **[3](#T3){ref-type="table"}**).

The concordance between the different methods was evaluated by McNemar test. Differences in proportions were evaluated by the Person χ^2^ test. Survival was calculated by the method described by Kaplan and Meier and comparisons performed by the log-rank test. Progression free survival (PFS) was defined as the interval between diagnosis and relapse of cervical cancer and disease specific survival (DSS) as the interval between diagnosis and cervical cancer related death. A Cox proportional hazards regression model was used for both univariate and multivariate evaluation of survival rates. In the multivariate analysis, forward and backward stepwise regression was used. All calculations were performed using the SPSS 15.0 statistical software package (SPSS, Chicago, IL). A *p*\< 0.05 was considered statistical significant.

RESULTS
=======

In total, 196 of the 202 (97%) samples have previously been found to harbour an HPV infection \[[@R25]\]. By type-specific PCR, high-risk HPV (types 16, 18, 31, 33, 35, 45, 52 and 58) DNA has previously been detected in 186 of the 202 (92.1%) samples. By NASBA, high-risk HPV (types 16, 18, 31, 33, 35, 45, 52 and 58) E6/E7 mRNA was detected in 186 of the 202 (92.1%) samples. The results for these two methods were similar (p = 1.00) (Table **[4](#T4){ref-type="table"}**), with divergence in only 4 cases, as two of the cases positive by type-specific PCR (HPV 16 and 33) were negative for HPV E6/E7 mRNA (case 3307 and 3959), and two cases positive for HPV E6/E7 mRNA (HPV 31 and 45) were negative by type-specific PCR \[[@R25]\]. It is important to notice, that sample 3307 and 3959 originally were negative by all methods and became positive by type-specific PCR only when tested on 10 times more concentrated material (nevertheless remaining RNA negative). The quality of the RNA within the sample was not investigated at the time of HPV detection as NASBA in general was performed successfully as shown by detectable mRNA expressed from the housekeeping gene U1A. The positivity rate for NASBA and type-specific PCR is presented in Table **[1](#T1){ref-type="table"}**. Out of 16 cases testing negative by type-specific PCR and NASBA, seven cases were previously found to be positive for another HPV type (HPV 6, 26, 66, 69, and 73) by consensus Gp5+/6+ PCR and RLB \[[@R25]\]. Moreover, one additional HPV 18 infection was found by RLB and ISH.

ISH detected HPV 16, 18, 31 and 33 DNA in 158 of the 202 (78.2%) samples (Table **[1](#T1){ref-type="table"}**). Detailed results have been presented previously \[[@R25]\]. The physical state of HPV DNA was determined by the pattern of the ISH signal. In 84 (53.2%) of samples a punctuate signal, indicating integrated virus DNA was seen, in 74 (46.8%) samples both diffuse and punctuate signals indicating both integrated and episomal viral DNA were seen, while none of the samples had only diffuse signal indicative of episomal viral DNA only.

Mutation analyses of the *TP53* gene revealed mutations in 3 of the 6 HPV negative samples (50%) (Table **[5](#T5){ref-type="table"}**).

HPV of any type tended to be detected less frequently by increasing age of the patients. This trend obtained statistical significance for high-risk HPV (group no. 1, Table **[3](#T3){ref-type="table"}**) when based on results obtained with NASBA (p = 0.04) and all methods collectively (p = 0.03). In line with this, absence of HPV 16/18 with all methods (group no. 5, Table **[3](#T3){ref-type="table"}**) was significantly correlated with higher age (p = 0.03). No correlation was found to FIGO stage.

FIGO stage was a strong indicator of survival in both univariate and multivariate analysis as shown in Table **[6](#T6){ref-type="table"}**. Age was of statistical significance in univariate but not in the multivariate analysis.

Based on the HPV E6/E7 mRNA (NASBA) results, patients testing negative had a statistically significant poorer DSS in univariate analysis than those testing positive, as shown in Fig. (**[1](#F1){ref-type="fig"}**) (p = 0.03), while the difference in PFS did not obtain statistical significance (p = 0.10). Comparing high-risk HPV *vs* HPV 6, 26, 66, 69 and 73 *vs* HPV negative (group no. 8, Table **[3](#T3){ref-type="table"}**, all methods collectively) HPV negative cases had a statistically significant poorer DSS in univariate analysis that the two other groups (p = 0.03) (Fig. **[2](#F2){ref-type="fig"}**), whereas no statistical significance was seen for PFS (p = 0.18). For the multivariate analysis, we combined the HPV high-risk group with the HPV 6, 26, 66, 69, 73 group because women in these categories were found to be of similar risk. In the multivariate analysis of DSS (Table **[6](#T6){ref-type="table"}**), the high-risk HPV E6/E7 mRNA (NASBA) and HPV high-risk/HPV 6, 26, 66, 69, 73 (all methods collectively) negative status obtained independent significance. The differences in both PFS and DSS became smaller when based on the results from the other groups and methods for HPV detection and was not of statistical significance.

DISCUSSION
==========

In this study, we have investigated the relation of the presence of HPV DNA and/or HPV E6/E7 mRNA, as well as the physical state of HPV DNA, with the clinical outcome of 202 women treated for cervical SCC. We were particularly interested in comparing the physical state of HPV DNA detected by ISH, and HPV E6/E7 mRNA expression, detected by NASBA, with clinical outcome. Only two studies have previously compared the physical state of HPV DNA, detected by ISH, and clinical outcome \[[@R23], [@R24]\] and no study has this far investigated the association between HPV E6/E7 mRNA detected by NASBA and prognosis.

Regarding the relation between HPV status and age, it has previously been reported that women with HPV DNA negative tumours were older than women with HPV DNA positive tumours \[[@R3], [@R4], [@R9]\]. In a study of Schwartz and colleagues \[[@R13]\], however, no association between HPV DNA data and age was demonstrated. Also, in some previous studies, infections with HPV 16 \[[@R10],[@R11]\], HPV 33/35 \[[@R2]\] and HPV types other than HPV 16/18 \[[@R11]\] have been found to increase with age, whereas in other studies, HPV 16 \[[@R2]\] and HPV 18 \[[@R11]\] infections were found to be frequent also in lower age groups. In the present study, high-risk HPV negatives by NASBA, as well as HPV negatives by all methods, was significantly correlated with higher age. This was also the case for HPV 16/18 negatives based on all methods collectively. In summary, such conflicting results may be explained by variation in terms of HPV detection methods, number and type of HPV types detected by the assay used, patient selection, or number of patients included in the different studies.

The differences in HPV status between the results obtained by NASBA and type-specific PCR were small with discordance in only 4 of 202 samples (2%) and therefore, the clinical relevance is questionable. It is possible that the minor differences between type-specific PCR and NASBA may reflect accidental circumstances or poor sample quality, rather than the actual absence of HPV DNA or mRNA in the respective samples. This is supported by the fact that the samples 3307 and 3959 became positive by type-specific PCR only when tested on 10 times more concentrated material. Furthermore, we cannot exclude the possibility that these differences may be explained by a possible degradation of HPV mRNA, for example in case of suboptimal freezing procedures for the tissue directly following the operation of the patient. On the other hand, we cannot either exclude that the differences actually reflect a higher amount of DNA present as compared to E6/E7 mRNA, and vice versa, as may be seen for example in relation to the integrated form of the virus: Several viral copies may be integrated as concatemers in the human genome; however, expression of the viral oncogenes may be silenced by host regulatory mechanisms. Yet, since the E6 and E7 proteins are shown to be necessary for malignancy, this situation is questionable. Alternatively, only one or two viral copies may be integrated, exerting a high level of E6/E7 expression, explaining the DNA negative/mRNA positive result; the negative DNA result may therefore be explained by low analytical sensitivity of the PCR method. Another explanation for the different results by the two methods might be mutations or deletions in the HPV target sequences. Deletions of larger regions of the HPV genome can be seen for example upon chromosomal integration, with the interruption within the E1 or E2 gene and the possible deletion of downstream sequences as the E5, L2, and L1 genes.

The survival analysis of our data suggests that patients negative for high-risk HPV (types 16, 18, 31, 33, 35, 45, 52 and 58) E6/E7 mRNA (NASBA) or negative for HPV high-risk/HPV 6, 26, 66, 69 and 73 (all methods collectively) had a poorer DSS than patients positive for these HPV groups. This is in accordance with the data of Higgins *et al.* \[[@R3]\] investigating HPV 16, 18, 31 and 33 mRNA expression using ISH and ^125^I-labelled riboprobes and the work of DeBritton *et al.* \[[@R4]\] identifying HPV 16, 18 and 33 using PCR, Southern blot and slot blot techniques. However, possible underlying biological mechanisms of this phenomenon remain to be elucidated. One possible explanation may be related to HPV unrelated genetic aberrations. We have previously found that in HPV negative cervical carcinomas, compared to HPV positive cases, *TP53* mutations are frequently identified \[[@R31]\], which results in lack of functional p53 protein and a possibly more aggressive tumour. This is supported by this study, where we show that 3 of 6 (50%) of the HPV negative cases had *TP53* mutations. In general, in cervical carcinomas lacking HPV E6/E7 mRNA expression (or in which the oncogenic expression is kept low), also additional molecular aberrations may exist that increase the carcinogenic potential and aggressiveness of the tumour or which may decrease the sensitivity to radiation therapy. In other words, other progression factors than the action of the E6/E7 oncoproteins may in a small number of cases play a more important role at a later stage in the progression of cancer. It should also be mentioned that the number of cases negative for HPV was low and the results have to be confirmed in larger studies.

Based on the results of PCR and ISH, the presence of HPV DNA was not found to be a prognostic factor in cervical SCCs. Similar findings have been reported by others \[[@R7]-[@R10]\]. However, these observations in turn contradict other investigations; using multivariate analysis, Riou *et al.* \[[@R2]\] and deBritton *et al.* \[[@R4]\] reported that patients negative for HPV DNA had a poorer prognosis than patients positive for HPV DNA. These conflicting results may be due to the small number of negative cases included and additional studies are needed in order to reveal whether the detection of HPV by a specific method may be of prognostic value in assessing survival.

When it comes to the individual HPV types, reduced survival has in particular been correlated with HPV 18 positive tumours \[[@R11]-[@R15]\]. Our results, however, show that neither HPV 18 DNA nor HPV 18 E6/E7 mRNA had any correlation to clinical outcome. Also, it is known that adenocarcinomas have a higher prevalence of HPV 18 than SCCs \[[@R12]-[@R15]\] and for patients with advanced adenocarcinoma, a significantly worse prognosis has been reported \[[@R32]\]. The differences may therefore be explained by the fact that our series consisted of SCCs only, whereas in the other studies both SCCs, adenocarcinomas and adenosquamous carcinomas were included \[[@R11]-[@R15]\]. Reduced survival has also been demonstrated for women with multiple HPV types. Our results show no correlation of multiple types with clinical outcome.

In addition to specific HPV types, HPV DNA integration status has also been suggested to play a role for the clinical outcome of cervical SCCs. In the present study, integrated HPV was detected by ISH; however did not correlate with either DSS or PFS free survival. Previously, only one research group has used ISH to compare the physical state of HPV and clinical outcome for patients with cervical carcinoma \[[@R23], [@R24]\]. In these studies, including 47 and 50 patients respectively, PFS was shorter for the women with tumours containing integrated HPV DNA than for the women with tumours containing episomal or episomal/integrated HPV DNA \[[@R23], [@R24]\]. In two studies using the E2/E6 ratio PCR assay for determining the integration status (based on the fact that E2 is generally disrupted upon integration \[[@R33]\]), including 50 and 158 patients respectively, it was reported that viral integration was significantly associated with decreased PFS \[[@R24], [@R34]\]. Another study including 40 patients, reported that HPV 16 positive tumours with a disrupted E2 gene had a tendency towards a shorter progression free survival \[[@R35]\]. In contrast to these studies, but in agreement with our data, Szarka *et al.* \[[@R36]\] used southern blot hybridization and E1/E2 *vs* E6 specific PCR on a series of 41 cervical cancers and found that HPV 16 integration did not correlate with progression free survival. One explanation for the discrepancy of previous results \[[@R23], [@R24], [@R35],[@R36]\] may be the small number of patients investigated, or may possibly also be related to differences in terms of the detection assays. In general, the clinical outcome and values of prognostic significance are obviously strongly associated with the method used and also with the number of and specific types included in the assay.

CONCLUSION
==========

The presence of high-risk HPV DNA (types 16, 18, 31, 33, 35, 45, 52 and 58), as well as the physical state of the virus, was not significantly associated with clinical outcome. Moreover, no differences in survival of women harbouring specific HPV types were seen. Concerning high-risk HPV E6/E7 mRNA (detected by NASBA) and HPV high-risk/HPV 6, 26, 66, 69 and 73 (all methods collectively), absence may appear to be associated with poor DSS; however, due to the low number of cases negative for HPV, the results should be confirmed in larger studies. To our point of view, in order to better consider the prognosis of women with cervical carcinoma, a better delineation of the total genetic changes (including among others *TP53* mutations), not only the HPV status, would be necessary.
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![Kaplan and Meier curves of DSS related to HPV E6/E7 mRNA expression detected by NASBA. High-risk HPV E6/E7 mRNA negative cases (n = 16) had a significantly worse DSS than those cases with detectable high-risk HPV E6/E7 mRNA (n = 186) (*p* = 0.03). The p-value differs slightly from that in Table [3](#T3){ref-type="table"} due to the use of the log-rank test as opposed to the Cox regression analysis in Table [3](#T3){ref-type="table"}.](TOVJ-2-74_F1){#F1}

![Kaplan and Meier curves of DSS related to the combination of high-risk HPV cases (n = 189) *vs* HPV 6, 26, 66, 69 and 73 cases (n = 7) vs HPV negative cases (n = 6) (all methods collectively). HPV negative cases had a significantly worse DSS than the two other groups (p = 0.03).](TOVJ-2-74_F2){#F2}

###### 

HPV Detection in Relation to Method and Clinico-Pathological Variables

  Variables         No. of Cases   NASBA[1](#T1FN1){ref-type="table-fn"} HPV Positive (%)   Type-Specific PCR[2](#T1FN2){ref-type="table-fn"} HPV Positive (%)   ISH[3](#T1FN3){ref-type="table-fn"} HPV Positive (%)
  ----------------- -------------- -------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------
  *Age*                                                                                                                                                          
  ≤ 50              85             83 (97.6)                                                81 (95.3)                                                            69 (81.2)
  51-70             67             59 (88.0)                                                61 (91.0)                                                            51 (76.2)
  \>70              50             44 (88.0)                                                44 (88.0)                                                            38 (76.0)
  *FIGO*                                                                                                                                                         
  I (IA-IB)         58             54 (93.1)                                                54 (93.1)                                                            46 (79.3)
  II (IIA-IIB)      82             77 (93.9)                                                76 (92.7)                                                            63 (76.8)
  III (IIIA-IIIB)   40             34 (85.0)                                                35 (87.5)                                                            32 (80.0)
  IV (IVA-IVB)      22             21 (95.5)                                                21 (95.5)                                                            17 (77.3)

NASBA: Nucleic acid sequence based amplification; HPV 16, 18, 31, 33, 35, 45, 52, and 58 E6/E7 mRNA \[[@R25]\].

PCR: Polymerase chain reaction; HPV 16, 18, 31, 33, 35, 45, 52, and 58 DNA \[[@R25]\].

ISH: *In situ* hybridization; HPV 16, 18, 31 and 33 DNA \[[@R25]\].

###### 

*TP53* Gene Sequencing Primers

  Exons   Forward Primer (5')                                          Reverse Primer (3')                                           PCR Fragment Length (bp)
  ------- ------------------------------------------------------------ ------------------------------------------------------------- --------------------------
  2,3     [a](#T2FN2){ref-type="table-fn"}GGAGTGCTTGGGTTGTGGT          [b](#T2FN3){ref-type="table-fn"}CGGCAAGGGGGACTGTA             586
  4       [a](#T2FN2){ref-type="table-fn"}GACTTCCTGAAAACAACG           [b](#T2FN3){ref-type="table-fn"}CACACATTAAGTGGGTAAAC          593
  5,6     [a](#T2FN2){ref-type="table-fn"}TTT CTT TGC TGC CGT CTTC     [b](#T2FN3){ref-type="table-fn"}TTG CAC ATC TCA TGG GGT TA    588
  7       [a](#T2FN2){ref-type="table-fn"}GAC CAT CCT GGC TAA CGG      [b](#T2FN3){ref-type="table-fn"}CAC AGG TTA AGA GGT CCC AAA   595
  8,9     [a](#T2FN2){ref-type="table-fn"}TTT GGG ACC TCT TAA CCT GT   [b](#T2FN3){ref-type="table-fn"}CAG GCA AAG TCA TAG AAC CAT   733
  10      [a](#T2FN2){ref-type="table-fn"}CAT GTT GCT TTT GTA CCG TC   [b](#T2FN3){ref-type="table-fn"}GGC AAG AAT GTG GTT ATA GGA   396
  11      [a](#T2FN2){ref-type="table-fn"}AAG GGA AGA TTA CGA GACT     [b](#T2FN3){ref-type="table-fn"}TAA GCT GGT ATG TCC TAC TC    500

All primers are linked to universal M13 sequences in the 5\` position:

M13F: TGT AAA ACG ACG GCC AGT (forward).

M13R: CAG GAA ACA GCT ATG ACC (reverse).

###### 

Groups for Statistical Evaluation. The Different HPV Detection Methods were Evaluated Either Individually (I) and/or Collectively (C)

  ---- ------------------------------------------------------------------------------------ ---------
  1    High-risk HPV positive *vs* high-risk HPV negative                                   I + C
  2    HPV 16 *vs* HPV 18 *vs* other HPV types *vs* multiple HPV *vs* HPV negative          I + C
  3    HPV 16 *vs* all other HPV positives and negatives                                    I + C
  4    HPV 18 *vs* all other HPV positives and negatives                                    I + C
  5    HPV 16/18 *vs* all other HPV positives and negatives                                 I + C
  6    HPV 16 *vs* HPV 18                                                                   I + C
  7    HPV 16 *vs* HPV 18 *vs* all other HPV positives and negatives                        I + C
  8    High-risk HPV *vs* HPV 6, 26, 66, 69, 73 *vs* HPV negative                           C
  9    HPV 6, 26, 66, 69, 73 *vs* HPV negative                                              C
  10   Single *vs* multiple infections                                                      C
  11   HPV punctuate signal *vs* HPV punctuate/diffuse signal *vs* HPV negative             I (ISH)
  12   HPV 16 punctuate signal *vs* HPV 16 punctuate/diffuse signal *vs* HPV 16 negative.   I (ISH)
  ---- ------------------------------------------------------------------------------------ ---------

High-risk HPV = HPV 16, 18, 31, 33, 35, 45, 52 and 58.

###### 

Association Between HPV DNA and mRNA

  NASBA[1](#T4FN1){ref-type="table-fn"}   Type-Specific PCR[2](#T4FN2){ref-type="table-fn"}         
  --------------------------------------- --------------------------------------------------- ----- -----
  HPV negative                            14                                                  2     16
  HPV positive                            2                                                   184   186
  Total                                   16                                                  186   202

NASBA: Nucleic acid sequence based amplification; HPV 16, 18, 31, 33, 35, 45, 52, and 58 E6/E7 mRNA \[[@R25]\].

PCR: Polymerase chain reaction; HPV 16, 18, 31, 33, 35, 45, 52, and 58 DNA \[[@R25]\].

###### 

Mutation Analysis of the TP53 Gene in HPV Negative SCCs.

  Sample   *TP53*Status   Affected Exon   Affected Codon   Codon Alteration   Amino Acid Alteration   HGVS Nomenclature
  -------- -------------- --------------- ---------------- ------------------ ----------------------- -------------------
  3596     Mut            7               245              GGC→AGC            Gly→Ser                 c.733G\>A
  3655     Mut            5               177              CCC→TCC            Pro→Ser                 c.529C\>T
  3754     WT                                                                                         
  3951     WT                                                                                         
  3952     WT                                                                                         
  3957     Mut            5               141              TGC→TGA            Cys→Stop                c.423C\>A

Mut = Mutation.

WT = Wild type.

###### 

Cox Regression Analysis of Disease Specific Survival (DSS) and Progression Free Survival (PFS)

  Variables                                                                       Univariate Analysis   Multivariate Analysis                                
  ------------------------------------------------------------------------------- --------------------- ----------------------- --------- ------ ----------- ---------
  **DSS**                                                                                                                                                    
    FIGO stage                                                                    2.2                   1.72-2.74               \<0.001   2.22   1.75-2.81   \<0.001
    Age group                                                                     1.7                   1.30-2.27               \<0.001                      
    Collective (HPV HR *vs* HPV X *vs* HPV neg)[c](#T6FN5){ref-type="table-fn"}   1.7                   1.05-2.82               0.03      3.24   1.14-9.19   0.03
    NASBA (HPV HR pos *vs* HPV HR neg)                                            2.1                   1.05-4.28               0.04      2.42   1.20-4.88   0.01
  **PFS**                                                                                                                                                    
    FIGO stage                                                                    2.1                   1.68-2.66               \<0.001   2.11   1.68-2.66   \<0.001
    Age group                                                                     1.4                   1.10-1.90               0.008                        

Hazard risk.

95% confidence interval of the hazard risk.

HR = high-risk HPV 16, 18, 31, 33, 35, 45, 52 and 58.

X = HPV 6, 26, 66, 69 and 73.

In the multivariate analysis two groups HPV HR/X *vs* HPV neg were tested.

Pos = positive; neg = negative.
